Resources
AMR Action Fund Announces First Investments in Adaptive Phage Therapeutics and Venatorx Pharmaceuticals
AMR Action Fund Announces First Investments in Adaptive Phage Therapeutics and Venatorx Pharmaceuticals Deals mark an important...
Read MoreAMR Action Fund Opens European Office
AMR Action Fund Opens European Office Swiss office positions Fund to pursue investment opportunities on a truly global scale
AMR Action Fund Appoints Scientific Advisory Board
This move brings the Fund, launched one year ago, one step closer to delivering 2 to 4 new antibiotics to...
A timely reality check on silent pandemic of antimicrobial resistance
A timely reality check on silent pandemic of antimicrobial resistance
We must fix the business model for new antibiotics
AMR Action Fund CEO Henry Skinner and BIO CEO Dr. Michelle McMurry-Heath co-authored a Fortune op-ed on policy solutions to the...
Pressure grows for market reforms to help tackle ‘silent pandemic’ of AMR
The Financial Times reported on the challenges of bringing new antibiotics to market and the growing political will to remedy the...
More Investment Sorely Needed to Combat Antimicrobial Resistance
MedPage today reported on the struggles that some biotechs face as they develop antibiotics. The article featured news from the...
Antibiotic resistance in the patient with cancer
The current focus on the coronavirus disease 2019 (COVID-19) pandemic means a lack of attention to other health challenges, such as antimicrobial resis- tance.
